Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – What’s Next?

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped down before the market opened on Tuesday . The stock had previously closed at $77.00, but opened at $73.10. Zealand Pharma A/S shares last traded at $74.00, with a volume of 2,240 shares.

Wall Street Analyst Weigh In

ZLDPF has been the subject of several research reports. Zacks Research upgraded Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 15th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research note on Tuesday, December 16th. Finally, BTIG Research upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Friday, November 28th. Six research analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Zealand Pharma A/S presently has a consensus rating of “Strong Buy”.

Zealand Pharma A/S Price Performance

The business’s fifty day moving average price is $76.67 and its 200-day moving average price is $68.33. The company has a market capitalization of $5.26 billion, a P/E ratio of 5.32 and a beta of 0.72. The company has a current ratio of 14.10, a quick ratio of 14.10 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.21. Zealand Pharma A/S had a return on equity of 55.76% and a net margin of 71.79%.The business had revenue of $7.76 million for the quarter, compared to the consensus estimate of $4.54 million. As a group, sell-side analysts predict that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.